|
Home
Search
Study Topics
Glossary
|
| Study 8 of 33 for search of: | nia OR national institute on aging | received from 03/31/2008 to 03/31/2009 |
|
Previous Study | Return to Search Results | Next Study |
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | National Institute on Aging (NIA) |
|---|---|
| Information provided by: | National Institute on Aging (NIA) |
| ClinicalTrials.gov Identifier: | NCT00744120 |
Purpose
This follow-up protocol is designed to evaluate participants who have previously been lymphoma patients treated on approved clinical studies of the National Institutes of Health.
| Condition |
|---|
|
Lymphoma |
| Study Type: | Observational |
| Study Design: | Cohort, Retrospective |
| Official Title: | Lymphoma Follow-up Protocol |
Blood serum
| Estimated Enrollment: | 800 |
| Study Start Date: | October 2003 |
| Estimated Study Completion Date: | December 2012 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
The intent of this protocol is to accrue up to 800 volunteers who are interested in participating in NIA research studies as part of follow-up for previous cancer treatment at NIH. Participants will be asked to answer questions regarding their general health status, diagnoses, and admissions to hospital, and to provide possible documentation. They may be asked to come to the NIA Clinical Research Unit at Harbor Hospital to participate in a follow-up evaluation. They will have the opportunity to obtain additional information about studies in which they may wish to participate and to discuss eligibility issues with NIA staff members. Any identified clinical problems in need of care will also be discussed. Volunteers may be referred, with their permission, to their private medical doctor for follow-up. They may be re-evaluated within a year for further follow-up.
The follow-up evaluation may include history and physical, blood and urine tests, questionnaire, MRI or CT.
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients, previously entered on NIH study who may be eligible if they have rare, unusual, interesting or unknown conditions that require diagnosis
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Patricia L. Duffey, RN | 410-350-3947 | protocol@grc.nia.nih.gov |
| Contact: Shelby Fiem, RN | 410-350-3922 | fiems@nia.nih.gov |
| United States, Maryland | |
| NIA Clinical Research Unit | Recruiting |
| Baltimore, Maryland, United States, 21225 | |
| Contact: Patricia L. Duffey, RN 410-350-3950 Duffeyp@grc.nia.nih.gov | |
| Contact: Shelby Fiem, RN 410-350-3922 fiems@nia.nih.gov | |
| Principal Investigator: Dan L. Longo, MD | |
| Sub-Investigator: Michele K. Evans, MD | |
| Principal Investigator: | Dan L. Longo, MD | National Institute on Aging (NIA) |
More Information
| Responsible Party: | National Institute on Aging / NIH ( Dan L. Longo, MD ) |
| Study ID Numbers: | AG0108 |
| Study First Received: | August 28, 2008 |
| Last Updated: | December 17, 2009 |
| ClinicalTrials.gov Identifier: | NCT00744120 History of Changes |
| Health Authority: | United States: Federal Government |
|
cancer |
|
Lymphatic Diseases Neoplasms Immunoproliferative Disorders Neoplasms by Histologic Type |
Immune System Diseases Lymphoproliferative Disorders Lymphoma |